ArticleFrontiers in oncology2025
Efficacy and safety of antiangiogenic agents combined with HIFU in the treatment of advanced liver cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although antiangiogenic agents and HIFU (High-intensity focused ultrasound) are extensively used in the systematic treatment of advanced primary and secondary liver cancer, respectively, the efficacy and safety of their combination remain unclear. Thus, this study aimed to investigate the efficacy, safety, and synergistic effect of the combination of antiangiogenic drugs with HIFU in the treatment of advanced liver cancer. Methods: Advanced liver cancer patients undergoing HIFU were included and matched 1:1 to two groups based on admission criteria: patients who received HIFU combined with antiangiogenic agents were assigned to the Combined HIFU group, whereas those who received HIFU but not antiangiogenic agents were assigned to the Only HIFU group. Then, therapeutic parameters, short-term efficacy, long-term survival, and safety of HIFU were analyzed and compared in this study. Results: There were 25 cases in both the Combined HIFU and Only HIFU groups. A significant difference was noted in the median ultrasound grayscale (hyperechoic region) occurrence time between the two groups ( Conclusion: Antiangiogenic agents combined with HIFU are effective and safe in the treatment of advanced primary and secondary liver cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.